Select a medication above to begin.
Enbrel
etanercept
Black Box Warnings .
Serious Infection Risk
weigh tx benefit vs. risk in patients w/ chronic or recurrent infection; pulmonary and extrapulmonary tuberculosis (TB), invasive fungal infections, and other opportunistic infections incl. Legionella and Listeria observed; some infections have been fatal; most infections occur in combo w/ other immunosuppressants; evaluate for TB risk factors and screen for latent TB infection before and during etanercept tx; initiate anti-TB tx before etanercept tx; monitor for infection signs/symptoms during and after etanercept tx; since active TB has developed in patients w/ negative tuberculin skin test, monitor all patients for active TB signs/symptoms; since histoplasmosis may be present in patients w/ negative antigen and antibody tests, consider empiric antifungal tx in patients w/ severe systemic illness if at risk for invasive fungal infection; D/C etanercept tx if serious infection or sepsis occurs
Malignancy
lymphoma and other malignancies, some fatal, reported in children and adolescents treated w/ TNF blockers
Adult Dosing .
Dosage forms: INJ (SureClick auto-injector): 50 mg; INJ (Mini cartridge): 50 mg; INJ (pre-filled syringe): 25 mg per 0.5 mL, 50 mg per mL; INJ (vial): 25 mg per mL, 25 mg per 0.5 mL
rheumatoid arthritis, mod-severe
- [50 mg SC qwk]
- Alt: 25 mg SC 2x/wk 72-96h apart
psoriatic arthritis
- [50 mg SC qwk]
- Alt: 25 mg SC 2x/wk 72-96h apart
ankylosing spondylitis
- [50 mg SC qwk]
- Alt: 25 mg SC 2x/wk 72-96h apart
psoriasis, mod-severe chronic plaque
- [50 mg SC qwk]
- Start: 50 mg SC 2x/wk x3mo; Alt: 25 mg SC 2x/wk 72-96h apart
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (SureClick auto-injector): 50 mg; INJ (Mini cartridge): 50 mg; INJ (pre-filled syringe): 25 mg per 0.5 mL, 50 mg per mL; INJ (vial): 25 mg per mL, 25 mg per 0.5 mL
polyarticular juvenile idiopathic arthritis, moderate-severe
- [2-17 yo, <63 kg]
- Dose: 0.8 mg/kg/dose SC qwk; Max: 50 mg/wk; Alt: 0.4 mg/kg/dose SC 2x/wk 72-96h apart
- [2-17 yo, >63 kg]
- Dose: 50 mg SC qwk; Alt: 25 mg SC 2x/wk 72-96h apart
psoriasis, mod-severe chronic plaque
- [4-17 yo, <63 kg]
- Dose: 0.8 mg/kg/dose SC qwk; Max: 50 mg/wk; Alt: 0.4 mg/kg/dose SC 2x/wk 72-96h apart
- [4-17 yo, >63 kg]
- Dose: 50 mg SC qwk; Alt: 25 mg SC 2x/wk 72-96h apart
psoriatic arthritis
- [2-17 yo, <63 kg]
- Dose: 0.8 mg/kg/dose SC qwk; Max: 50 mg/wk; Alt: 0.4 mg/kg/dose SC 2x/wk 72-96h apart
- [2-17 yo, >63 kg]
- Dose: 50 mg SC qwk; Alt: 25 mg SC 2x/wk 72-96h apart
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- granulomatosis w/ polyangiitis use
- infection, active
- caution: infection, chronic
- caution: infection, recurrent
- caution: infection risk
- caution: patients >65 yo
- caution: diabetes mellitus, uncontrolled
- caution: opportunistic infection history
- caution: TB infection, latent
- caution: TB infection risk
- caution: residents of area w/ endemic TB
- caution: residents of area w/ endemic mycosis
- caution: travelers in area w/ endemic TB
- caution: travelers in area w/ endemic mycosis
- caution: HBV infection
- caution: HBV infection history
- caution: alcoholic hepatitis, moderate-severe
- caution: malignancy history
- caution: malignancy risk
- caution: CHF
- caution: demyelinating dz
- caution: myelosuppression
- caution: myelosuppression history
Drug Interactions .
Overview
etanercept
TNF blocker
- cardiotoxic effects
- immunomodulatory effects
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abatacept
- abrocitinib
- adalimumab
- anakinra
- anifrolumab
- baricitinib
- canakinumab
- certolizumab pegol
- cladribine oral
- cyclophosphamide
- deuruxolitinib
- epirubicin
- etanercept
- etrasimod
- golimumab
- idarubicin
- infliximab
- natalizumab
- pimecrolimus topical
- rabies vaccine
- rilonacept
- ritlecitinib
- ruxolitinib topical
- sarilumab
- tocilizumab
- tofacitinib
- upadacitinib
- vedolizumab
Monitor/Modify Tx
- ado-trastuzumab emtansine
- aldesleukin
- anthrax vaccine
- asciminib
- avelumab
- axitinib
- bevacizumab
- bezlotoxumab
- binimetinib
- bortezomib
- capecitabine
- carfilzomib
- chikungunya vaccine
- COVID-19 vaccine
- dabrafenib
- daunorubicin
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- doxorubicin
- ebola vaccine, live
- encorafenib
- everolimus
- fam-trastuzumab deruxtecan
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- hydroxychloroquine
- ibrutinib
- ifosfamide
- imatinib
- influenza H5N1 vaccine
- influenza vaccine
- interferon beta 1a
- interferon beta 1b
- Japanese encephalitis vaccine
- lenvatinib
- margetuximab
- mavacamten
- meningococcal vaccine
- mirdametinib
- mitomycin
- mitoxantrone
- pazopanib
- peginterferon beta 1a
- pertuzumab
- pneumococcal vaccine
- poliovirus vaccine
- ponatinib
- propafenone
- respiratory syncytial virus vaccine
- ripretinib
- selumetinib
- sipuleucel-T
- sitagliptin
- smallpox/mpox vaccine, live
- sorafenib
- sunitinib
- temsirolimus
- tick-borne encephalitis vaccine
- tivozanib
- trastuzumab
- typhoid vaccine
- vandetanib
- zanidatamab
- zenocutuzumab
- zongertinib
Caution Advised
- abemaciclib
- acalabrutinib
- afamitresgene autoleucel
- alemtuzumab
- anti-thymocyte globulin
- atidarsagene autotemcel
- avacopan
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- belimumab
- belinostat
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- carboplatin
- carmustine
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- copanlisib
- corticotropin
- cortisone
- crovalimab
- cyclosporine
- cytarabine
- dactinomycin
- danicopan
- daratumumab
- decitabine
- deflazacort
- delgocitinib topical
- deucravacitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dupilumab
- duvelisib
- eculizumab
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- eribulin
- etoposide
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluorouracil
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- gemtuzumab ozogamicin
- glofitamab
- guselkumab
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- ibritumomab tiuxetan
- idecabtagene vicleucel
- idelalisib
- inebilizumab
- inotuzumab ozogamicin
- iptacopan
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- lifileucel
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- loteprednol ophthalmic
- lymphocyte immune globulin, anti-thymocyte globulin
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mogamulizumab
- momelotinib
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- nadofaragene firadenovec intravesical
- nelarabine
- nipocalimab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- panobinostat
- pegcetacoplan
- pentostatin
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- ravulizumab
- regorafenib
- risankizumab
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- satralizumab
- secukinumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- spesolimab
- sulfasalazine
- sutimlimab
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- topotecan
- tralokinumab
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- ustekinumab
- vamorolone
- venetoclax
- vilobelimab
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- zilucoplan
Adverse Reactions .
Serious Reactions
- infection, severe
- opportunistic infection
- tuberculosis
- HBV reactivation
- malignancy
- lymphoma
- leukemia
- skin CA
- hypersensitivity rxn
- anaphylaxis
- skin rxn, severe
- CHF
- neurologic disorders
- optic neuritis
- myelosuppression
- lupus-like syndrome
- hepatitis, autoimmune
- vasculitis
- sarcoidosis
- interstitial lung dz
- glomerulonephritis
Common Reactions
- infection
- URI
- injection site rxn
- diarrhea
- rash
- pruritus
- fever
- urticaria
Safety/Monitoring .
Monitoring Parameters
hepatitis B serology incl. HBsAg at baseline; TB test at baseline, then periodically; active TB signs/symptoms; dermatologic exams, especially if incr. skin CA risk
Look/Sound-Alike Drug Names
Enbrel confused with: Elavil; Levbid
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; risk of teratogenicity not expected based on conflicting human data; no known risk of fetal harm based on animal data at 48-58x systemic exposure; for infants exposed to etanercept in utero, weigh risk/benefit before admin. live vaccines
Lactation
Clinical Summary
may use while breastfeeding; no known risk of infant harm based on limited human data and drug properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: unknown; CYP450: unknown
Excretion: unknown; Half-life: 102h
Subclass: DMARDs, Tumor Necrosis Factor (TNF) Inhibitors ; Psoriasis, Systemic Agents ; Spondyloarthropathies
Mechanism of Action
binds and inhibits tumor necrosis factor, reducing inflammation and altering immune response
Formulary .
No Formulary Selected
Manufacturer/Pricing .
Manufacturer: Amgen, Inc. and Pfizer Inc.
DEA/FDA: Rx
Retail Price
Estimated prices only. For current pricing, visit GoodRx.
subcutaneous solution:
- 50 mg (1 carton, 4 sureclicks): $5,975.00
subcutaneous kit:
- 25 mg (1 carton, 4 vials): $2,987.00
subcutaneous solution:
- 50 mg (1 carton, 4 mini cartridges): $6,097.00
subcutaneous solution:
- 25 mg (2 carton, 4 syringes): $6,084.00
- 50 mg (1 carton, 4 syringes): $5,975.00
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.